Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Nephrology

Long-Term Monitoring and Planning for the Future

At a Glance

For autosomal dominant progressive nephropathy, follow-up is tailored to kidney function, its rate of change, blood pressure, urine albumin, and complications. Early education about transplant, dialysis, and supportive care helps you plan before a crisis.

Living with autosomal dominant progressive nephropathy is a marathon, not a sprint. While kidney function decline is typically slow, progression varies substantially by your specific gene, blood pressure, albuminuria, and recent eGFR trends [1]. You have the opportunity to take an active role in your long-term health.

Effective monitoring is about more than just numbers; it is a partnership between you and your care team to preserve your quality of life and prepare for the future with confidence [2][3].

Your Surveillance Routine

There is no one-size-fits-all schedule; monitoring frequency is individualized based on your eGFR category, rate of decline, medication changes, and any new complications. While your doctor will set a personalized plan, standard care generally follows these patterns:

  • Nephrology Visits: In stable, early-stage disease, you may see your nephrologist once or twice a year. As your eGFR (estimated glomerular filtration rate) drops, or if you have high potassium or new symptoms, these visits often increase [4][5].
  • Essential Lab Work:
    • eGFR and Creatinine: These measure how well your kidneys filter waste [6].
    • UACR (Urine Albumin-to-Creatinine Ratio): This checks for protein “leaking” into your urine, which is a key sign of kidney stress [6][7].
    • Potassium and Bicarbonate: Your kidneys regulate these vital chemicals. High potassium (hyperkalemia) or low bicarbonate (acidosis) can occur as function declines and may require dietary changes or medication [8][4]. You may also have diagnosis-specific surveillance, such as checking uric acid for ADTKD-UMOD.
  • Home Blood Pressure Monitoring (HBPM): This is one of the most powerful tools you have. Using a validated upper-arm cuff, you should ideally track your pressure in the morning and evening for several days before an appointment [9][10]. This helps your doctor distinguish between “white coat hypertension” (high readings only at the office) and your true daily average [10][11].

Managing the Psychological Toll

It is normal to feel “renal anxiety”—a specific type of distress related to the uncertainty of kidney disease and the fear of future failure [12][13].

  • Acknowledge the Burden: Studies show that up to 34% of people with chronic kidney disease experience symptoms of anxiety, and many others struggle with the “treatment burden” of diet and medication restrictions [12][3].
  • Support Strategies: Cognitive-behavioral therapy (CBT), regular physical activity, and peer support groups can significantly improve your quality of life [14][15]. Don’t hesitate to ask your care team for a referral to a social worker or a counselor who understands chronic illness [12].

Preparing for the Future

One of the most empowering steps you can take is “pre-planning.” This does not mean kidney failure is inevitable for everyone; it means you are exploring choices while you feel well rather than during a medical crisis.

  • Evaluation and Timing: In the US, you can begin the evaluation for a kidney transplant and start accruing formal “wait time” once your eGFR falls to 20 mL/min/1.73 m² or lower [16][17]. However, evaluations and living-donor discussions can begin earlier, and policies vary substantially by country.
  • Preemptive Transplantation: This is a transplant that happens before you ever need dialysis. While it is associated with advantages for suitable candidates and avoids the physical strain of dialysis, it carries lifelong immunosuppression and surgical risks, and is not a guaranteed option [18][19].
  • Education Early: Modern guidelines recommend beginning education about transplant, dialysis options (like hemodialysis or peritoneal dialysis), and conservative care when eGFR falls below 30 [5]. Dialysis initiation depends on symptoms and laboratory complications, not just a single eGFR threshold. This “Life-Plan” approach ensures your treatments align with your personal goals and lifestyle [20].

By staying consistent with your monitoring and being honest with your team about both your physical and emotional health, you can navigate the path ahead with a clear sense of direction [21][3].

Common questions in this guide

How often should I see my nephrologist and have kidney tests?
The schedule depends on your eGFR, how quickly kidney function is changing, medication changes, and any complications. People with stable, early-stage disease may have visits once or twice a year, while worsening kidney function or problems such as high potassium may require more frequent follow-up.
Which tests are used to monitor autosomal dominant nephropathy?
Common tests include eGFR and creatinine for kidney filtering, and a urine albumin-to-creatinine ratio to detect protein leaking into the urine. Blood potassium and bicarbonate help identify complications, and uric acid may be monitored in some forms such as ADTKD-UMOD. Home blood pressure readings also help show your usual blood pressure between visits.
How can home blood pressure readings help my kidney care?
Use a validated upper-arm cuff and record readings in the morning and evening for several days before an appointment. These readings can help your clinician compare your usual blood pressure with office readings and identify white coat hypertension.
When should I start discussing a kidney transplant?
In the United States, transplant evaluation and formal wait-time accrual can begin when eGFR reaches 20 or lower, although evaluation and living-donor conversations may start earlier. Timing and policies differ by country, so ask your nephrologist when planning should begin for you.
Does reaching a certain eGFR automatically mean I need dialysis?
No. Dialysis is usually started based on symptoms and complications shown by laboratory tests, not a single eGFR number. Education about hemodialysis, peritoneal dialysis, transplant, and conservative care is generally recommended before kidney function becomes severely reduced.
What can help with anxiety about progressive kidney disease?
Cognitive-behavioral therapy, physical activity, peer support groups, and counseling can help with distress and treatment burden. Ask your care team for a referral to a social worker or counselor who understands chronic kidney disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current 'eGFR slope'—how quickly has my kidney function changed over the last two years?
  2. 2.At what point in my disease progression do you typically recommend starting the evaluation for a kidney transplant?
  3. 3.Can you review my home blood pressure log to see if my 'white coat' office readings are higher than my daily averages?
  4. 4.Based on my current stage, how often should I be getting blood work for potassium and bicarbonate levels?
  5. 5.Are there specific patient support groups or counselors you recommend who specialize in 'renal anxiety' or chronic kidney disease?
  6. 6.If my family members want to be tested as potential donors, what is the independent process for them to be screened?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD.

    Econimo L, Schaeffer C, Zeni L, et al.

    Kidney international reports 2022; (7(11)):2332-2344 doi:10.1016/j.ekir.2022.08.012.

    PMID: 36531871
  2. 2

    Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

    Cheung AK, Chang TI, Cushman WC, et al.

    Kidney international 2021; (99(3)):559-569 doi:10.1016/j.kint.2020.10.026.

    PMID: 33637203
  3. 3

    Health-related quality of life in patients with chronic kidney disease.

    Hussien H, Apetrii M, Covic A

    Expert review of pharmacoeconomics & outcomes research 2021; (21(1)):43-54 doi:10.1080/14737167.2021.1854091.

    PMID: 33213186
  4. 4

    Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.

    Vassalotti JA, Centor R, Turner BJ, et al.

    The American journal of medicine 2016; (129(2)):153-162.e7.

    PMID: 26391748
  5. 5

    Management Options for an Older Adult With Advanced Chronic Kidney Disease and Dementia: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

    Burns RB, Waikar SS, Wachterman MW, Kanjee Z

    Annals of internal medicine 2020; (173(3)):217-225 doi:10.7326/M20-2640.

    PMID: 32745449
  6. 6

    Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review.

    Levey AS, Becker C, Inker LA

    JAMA 2015; (313(8)):837-46 doi:10.1001/jama.2015.0602.

    PMID: 25710660
  7. 7

    CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 Diabetes.

    Mullins CD, Pantalone KM, Betts KA, et al.

    Kidney medicine 2022; (4(11)):100532 doi:10.1016/j.xkme.2022.100532.

    PMID: 36339666
  8. 8

    Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.

    Agarwal R, Green JB, Heerspink HJL, et al.

    Journal of the American College of Cardiology 2026; (87(7)):772-784 doi:10.1016/j.jacc.2025.10.049.

    PMID: 41493296
  9. 9

    Blood Pressure Measurement: A KDOQI Perspective.

    Drawz PE, Beddhu S, Kramer HJ, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (75(3)):426-434 doi:10.1053/j.ajkd.2019.08.030.

    PMID: 31864820
  10. 10

    Blood pressure control in patients with chronic kidney disease according to office and home blood pressures.

    Chantrel F, Ott J, Dimitrov Y, et al.

    Blood pressure monitoring 2020; (25(5)):246-251 doi:10.1097/MBP.0000000000000463.

    PMID: 32842021
  11. 11

    Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements?

    Ruiz-Hurtado G, Gorostidi M, Waeber B, Ruilope LM

    Current opinion in nephrology and hypertension 2015; (24(6)):488-91 doi:10.1097/MNH.0000000000000162.

    PMID: 26371523
  12. 12

    Depression, Anxiety, Stress Symptoms and Health-Related Quality of Life in Hemodialysis Patients: Cross-Sectional Findings from a Romanian Cohort.

    Luca AL, Militaru F, Văduva CM, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(2)) doi:10.3390/medicina62020242.

    PMID: 41752642
  13. 13

    Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players.

    Domingo-Gallego A, Pybus M, Bullich G, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022; (37(4)):687-696 doi:10.1093/ndt/gfab019.

    PMID: 33532864
  14. 14

    Mental health and kidney disease.

    Chilcot J, Cogley C, Carswell C, et al.

    Nature reviews. Nephrology 2026; (22(5)):363-376 doi:10.1038/s41581-026-01055-3.

    PMID: 41606193
  15. 15

    The Impact of Digital Health Interventions on Psychological Health, Self-Efficacy, and Quality of Life in Patients With End-Stage Kidney Disease: Systematic Review and Meta-Analysis.

    Zhu J, Xie J, Luo Y, et al.

    Journal of medical Internet research 2025; (27()):e74414 doi:10.2196/74414.

    PMID: 41004280
  16. 16

    Racial Disparities in Eligibility for Preemptive Waitlisting for Kidney Transplantation and Modification of eGFR Thresholds to Equalize Waitlist Time.

    Ku E, McCulloch CE, Adey DB, et al.

    Journal of the American Society of Nephrology : JASN 2021; (32(3)):677-685 doi:10.1681/ASN.2020081144.

    PMID: 33622978
  17. 17

    Time trends in preemptive kidney transplantation in Europe: an ERA registry study.

    Kramer A, Boenink R, Mercado Vergara CG, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(12)):2100-2112 doi:10.1093/ndt/gfae105.

    PMID: 38724446
  18. 18

    What are the benefits of preemptive versus non-preemptive kidney transplantation? A systematic review and meta-analysis.

    Rana Magar R, Knight SR, Maggiore U, et al.

    Transplantation reviews (Orlando, Fla.) 2023; (37(4)):100798 doi:10.1016/j.trre.2023.100798.

    PMID: 37801855
  19. 19

    Quantifying lead time bias when estimating patient survival in preemptive living kidney donor transplantation.

    Irish GL, Chadban S, McDonald S, Clayton PA

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019; (19(12)):3367-3376 doi:10.1111/ajt.15472.

    PMID: 31132214
  20. 20

    KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.

    Lok CE, Huber TS, Lee T, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (75(4 Suppl 2)):S1-S164 doi:10.1053/j.ajkd.2019.12.001.

    PMID: 32778223
  21. 21

    Chronic kidney disease.

    Kalantar-Zadeh K, Jafar TH, Nitsch D, et al.

    Lancet (London, England) 2021; (398(10302)):786-802 doi:10.1016/S0140-6736(21)00519-5.

    PMID: 34175022

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and transplant team should interpret your results and recommend a plan for your specific situation.

Get notified when new evidence is published on Autosomal dominant progressive nephropathy with hypertension.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.